The global clinical trials support services market size is calculated at USD 27.09 billion in 2025 and is forecasted to reach around USD 53.71 billion by 2034, accelerating at a CAGR of 7.89% from 2025 to 2034. The North America market size surpassed USD 12.81 billion in 2024 and is expanding at a CAGR of 7.90% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Clinical Trials Support Services Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Clinical Trials Support Services Market, by Service
8.1.1 Clinical Trial Site Management
8.1.1.1. Market Revenue and Forecast
8.1.2. Data Management
8.1.2.1. Market Revenue and Forecast
8.1.3. Patient Recruitment Management
8.1.3.1. Market Revenue and Forecast
8.1.4. Administrative Staff
8.1.4.1. Market Revenue and Forecast
8.1.5. IRB
8.1.5.1. Market Revenue and Forecast
8.1.6. Others
8.1.6.1. Market Revenue and Forecast
9.1. Clinical Trials Support Services Market, by Phase
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast
9.1.2. Phase II
9.1.2.1. Market Revenue and Forecast
9.1.3. Phase III
9.1.3.1. Market Revenue and Forecast
9.1.4. Phase IV
9.1.4.1. Market Revenue and Forecast
10.1. Clinical Trials Support Services Market, by Sponsor
10.1.1. Pharmaceutical & Biopharmaceutical
10.1.1.1. Market Revenue and Forecast
10.1.2. Medical Devices
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Service
11.1.2. Market Revenue and Forecast, by Phase
11.1.3. Market Revenue and Forecast, by Sponsor
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Service
11.1.4.2. Market Revenue and Forecast, by Phase
11.1.4.3. Market Revenue and Forecast, by Sponsor
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Service
11.1.5.2. Market Revenue and Forecast, by Phase
11.1.5.3. Market Revenue and Forecast, by Sponsor
11.2. Europe
11.2.1. Market Revenue and Forecast, by Service
11.2.2. Market Revenue and Forecast, by Phase
11.2.3. Market Revenue and Forecast, by Sponsor
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Service
11.2.4.2. Market Revenue and Forecast, by Phase
11.2.4.3. Market Revenue and Forecast, by Sponsor
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Service
11.2.5.2. Market Revenue and Forecast, by Phase
11.2.5.3. Market Revenue and Forecast, by Sponsor
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Service
11.2.6.2. Market Revenue and Forecast, by Phase
11.2.6.3. Market Revenue and Forecast, by Sponsor
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Service
11.2.7.2. Market Revenue and Forecast, by Phase
11.2.7.3. Market Revenue and Forecast, by Sponsor
11.3. APAC
11.3.1. Market Revenue and Forecast, by Service
11.3.2. Market Revenue and Forecast, by Phase
11.3.3. Market Revenue and Forecast, by Sponsor
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Service
11.3.4.2. Market Revenue and Forecast, by Phase
11.3.4.3. Market Revenue and Forecast, by Sponsor
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Service
11.3.5.2. Market Revenue and Forecast, by Phase
11.3.5.3. Market Revenue and Forecast, by Sponsor
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Service
11.3.6.2. Market Revenue and Forecast, by Phase
11.3.6.3. Market Revenue and Forecast, by Sponsor
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Service
11.3.7.2. Market Revenue and Forecast, by Phase
11.3.7.3. Market Revenue and Forecast, by Sponsor
11.4. MEA
11.4.1. Market Revenue and Forecast, by Service
11.4.2. Market Revenue and Forecast, by Phase
11.4.3. Market Revenue and Forecast, by Sponsor
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Service
11.4.4.2. Market Revenue and Forecast, by Phase
11.4.4.3. Market Revenue and Forecast, by Sponsor
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Service
11.4.5.2. Market Revenue and Forecast, by Phase
11.4.5.3. Market Revenue and Forecast, by Sponsor
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Service
11.4.6.2. Market Revenue and Forecast, by Phase
11.4.6.3. Market Revenue and Forecast, by Sponsor
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Service
11.4.7.2. Market Revenue and Forecast, by Phase
11.4.7.3. Market Revenue and Forecast, by Sponsor
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Service
11.5.2. Market Revenue and Forecast, by Phase
11.5.3. Market Revenue and Forecast, by Sponsor
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Service
11.5.4.2. Market Revenue and Forecast, by Phase
11.5.4.3. Market Revenue and Forecast, by Sponsor
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Service
11.5.5.2. Market Revenue and Forecast, by Phase
11.5.5.3. Market Revenue and Forecast, by Sponsor
12.1. IQVIA Holding Inc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Icon PLC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. WuXi AppTec
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. LapCorp
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Alcura
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Parexel International
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Charles River Laboratories
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Eurofins Scientific SE
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. F.Hoffmann-La Roche Ltd
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Novo Nordisk A/S
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample